IL273411B2 - Antibody against PD-L1 and its uses - Google Patents

Antibody against PD-L1 and its uses

Info

Publication number
IL273411B2
IL273411B2 IL273411A IL27341120A IL273411B2 IL 273411 B2 IL273411 B2 IL 273411B2 IL 273411 A IL273411 A IL 273411A IL 27341120 A IL27341120 A IL 27341120A IL 273411 B2 IL273411 B2 IL 273411B2
Authority
IL
Israel
Prior art keywords
antibody
Prior art date
Application number
IL273411A
Other languages
English (en)
Hebrew (he)
Other versions
IL273411B1 (en
IL273411A (en
Inventor
Xiaoniu Miao
Huajing Hu
Junjian Liu
Bingliang Chen
Li Li
Original Assignee
Innovent Biologics Suzhou Co Ltd
Xiaoniu Miao
Huajing Hu
Junjian Liu
Bingliang Chen
Li Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd, Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li filed Critical Innovent Biologics Suzhou Co Ltd
Priority claimed from PCT/CN2018/124314 external-priority patent/WO2019129136A1/fr
Publication of IL273411A publication Critical patent/IL273411A/en
Publication of IL273411B1 publication Critical patent/IL273411B1/en
Publication of IL273411B2 publication Critical patent/IL273411B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL273411A 2017-12-27 2018-12-27 Antibody against PD-L1 and its uses IL273411B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711449321 2017-12-27
CN201811567281.3A CN109970857B (zh) 2017-12-27 2018-12-19 抗pd-l1抗体及其用途
PCT/CN2018/124314 WO2019129136A1 (fr) 2017-12-27 2018-12-27 Anticorps anti-pd-l1 et ses applications

Publications (3)

Publication Number Publication Date
IL273411A IL273411A (en) 2020-05-31
IL273411B1 IL273411B1 (en) 2025-11-01
IL273411B2 true IL273411B2 (en) 2026-03-01

Family

ID=67076314

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273411A IL273411B2 (en) 2017-12-27 2018-12-27 Antibody against PD-L1 and its uses
IL323534A IL323534A (en) 2017-12-27 2025-09-25 Anti-PD-L1 antibody and its uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323534A IL323534A (en) 2017-12-27 2025-09-25 Anti-PD-L1 antibody and its uses

Country Status (11)

Country Link
US (1) US11512131B2 (fr)
EP (1) EP3733704A4 (fr)
JP (2) JP7534954B2 (fr)
KR (1) KR102384845B1 (fr)
CN (2) CN109970857B (fr)
AU (1) AU2018395084B2 (fr)
BR (1) BR112020007725A2 (fr)
CA (1) CA3076447A1 (fr)
IL (2) IL273411B2 (fr)
SG (1) SG11202002530RA (fr)
TW (2) TWI763964B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (fr) 2017-08-07 2019-02-14 The Regents Of The University Of California Plate-forme de génération d'agents thérapeutiques cellulaires sans risque
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2020259593A1 (fr) * 2019-06-24 2020-12-30 信达生物制药(苏州)有限公司 Préparations contenant un anticorps anti-lag-3, leur procédé de préparation et leur utilisation
CN111848800B (zh) * 2020-07-31 2023-07-04 三优生物医药(上海)有限公司 Pd-l1单结构域抗体及其用途
CN112745391B (zh) * 2019-10-30 2022-11-22 三优生物医药(上海)有限公司 Pd-l1结合分子
EP4069738A1 (fr) * 2019-12-06 2022-10-12 SOTIO Biotech a.s. Anticorps humanisés anti-cldn18.2
CN113121686B (zh) * 2019-12-31 2025-12-02 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
CN114901695A (zh) * 2020-01-02 2022-08-12 南京金斯瑞生物科技有限公司 抗gitr抗体及其用途
CN111423515A (zh) * 2020-03-23 2020-07-17 倍而达药业（苏州）有限公司 一种cd20/cd47双特异性抗体及应用
CN111388665B (zh) * 2020-03-24 2022-09-16 中国医学科学院医药生物技术研究所 一种治疗肿瘤的复合物及其制剂和用途
WO2021226984A1 (fr) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 Anticorps bispécifique tétravalent contre pd-1 et pd-l1
EP4186522A1 (fr) * 2020-07-23 2023-05-31 Innovent Biologics (Suzhou) Co., Ltd. Préparation d'anticorps bispécifique pd-l1/lag-3, son procédé de préparation et son utilisation
TWI894360B (zh) * 2020-09-22 2025-08-21 大陸商南京聖和藥業股份有限公司 抗tigit抗體及雙抗體和它們的應用
WO2022105751A1 (fr) * 2020-11-19 2022-05-27 信达生物制药(苏州)有限公司 PROTÉINE DE FUSION TGFβRII
CA3173557A1 (fr) * 2021-01-06 2022-07-14 Li Peng Anticorps anti-pd-l1 et proteines de fusion de correspondantes
MX2023008172A (es) * 2021-01-08 2023-07-18 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
US20240301068A1 (en) * 2021-01-08 2024-09-12 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding with pd-l1 and antigen-binding fragment of antibody
JP2024509369A (ja) * 2021-02-10 2024-03-01 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ｐｄ－ｌ１抗体及びその使用
WO2022184155A1 (fr) * 2021-03-05 2022-09-09 南京圣和药业股份有限公司 Anticorps anti-ctla-4 et son utilisation
WO2022228431A1 (fr) * 2021-04-27 2022-11-03 上海君实生物医药科技股份有限公司 Anticorps à domaine unique anti-pd-l1 et son utilisation
TW202317608A (zh) * 2021-06-18 2023-05-01 大陸商杭州尚健生物技術有限公司 雙特異性融合蛋白
WO2023046113A1 (fr) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 Anticorps humanisé anti-pd-l1 humain ou fragment de liaison à l'antigène de celui-ci, et son utilisation
CN113943227B (zh) * 2021-11-29 2023-11-07 中南大学湘雅医院 化合物及含有该化合物的药物组合物及其用途
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用
WO2024140863A1 (fr) * 2022-12-29 2024-07-04 南京圣和药业股份有限公司 Anticorps ciblant crtam et pd-l1 et son utilisation
CN116063526B (zh) * 2022-12-31 2025-03-25 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024153068A1 (fr) * 2023-01-18 2024-07-25 Elpiscience (Suzhou) Biopharma, Ltd. Anticorps à domaine unique anti-pdl1, protéine de fusion et son utilisation
CN116535511B (zh) * 2023-06-30 2023-09-12 苏州驾玉生物医药有限公司 一种用于检测pd-l1的免疫组化抗体及其应用
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN119119278B (zh) * 2024-10-29 2025-03-21 海南大学 一种抗pd-l1蛋白的纳米抗体及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (fr) * 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2016111645A1 (fr) * 2015-01-09 2016-07-14 Agency For Science, Technology And Research Anticorps anti-pd-l1
WO2017118321A1 (fr) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anticorps anti-pd-l1 et utilisations associées
WO2017161976A1 (fr) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Nouveaux anticorps contre pd-l1
US20170362321A1 (en) * 2016-06-20 2017-12-21 Kymab Limited Antibodies and immunocytokines

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP1766396B1 (fr) 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101160324B (zh) 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
WO2008140621A2 (fr) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Virus oncolytiques transgéniques et leurs utilisations
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP4209510B1 (fr) * 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
SI2699264T1 (en) * 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
AU2014323523B2 (en) * 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CA2936244A1 (fr) * 2014-01-21 2015-07-30 Medimmune, Llc Compositions et procedes pour moduler et reorienter des reponses immunitaires
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015138920A1 (fr) 2014-03-14 2015-09-17 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
MA40682B1 (fr) 2014-03-31 2020-01-31 Hoffmann La Roche Anticorps anti-ox40 et procédés d'utilisation correspondants
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
JP6909153B2 (ja) * 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016061142A1 (fr) * 2014-10-14 2016-04-21 Novartis Ag Molécules d'anticorps de pd-l1 et leurs utilisations
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN106554416B (zh) * 2015-12-09 2019-03-15 聊城市奥润生物医药科技有限公司 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白（sting）激动剂在抗肿瘤中的应用
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
CN106478819B (zh) * 2016-10-27 2018-12-07 常州费洛斯药业科技有限公司 一种针对pd-l1的单克隆抗体或抗体片段
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005874A2 (fr) * 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2016111645A1 (fr) * 2015-01-09 2016-07-14 Agency For Science, Technology And Research Anticorps anti-pd-l1
WO2017118321A1 (fr) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anticorps anti-pd-l1 et utilisations associées
WO2017161976A1 (fr) * 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Nouveaux anticorps contre pd-l1
US20170362321A1 (en) * 2016-06-20 2017-12-21 Kymab Limited Antibodies and immunocytokines

Also Published As

Publication number Publication date
CA3076447A1 (fr) 2019-07-04
SG11202002530RA (en) 2020-04-29
JP2024164038A (ja) 2024-11-26
IL323534A (en) 2025-11-01
TWI772248B (zh) 2022-07-21
JP2021508436A (ja) 2021-03-11
CN109970857A (zh) 2019-07-05
CN109970857B (zh) 2022-09-30
EP3733704A4 (fr) 2021-12-29
TWI763964B (zh) 2022-05-11
AU2018395084A1 (en) 2020-04-09
US20200332009A1 (en) 2020-10-22
AU2018395084B2 (en) 2021-06-24
US11512131B2 (en) 2022-11-29
TW202231665A (zh) 2022-08-16
KR102384845B1 (ko) 2022-04-08
JP7534954B2 (ja) 2024-08-15
TW201927822A (zh) 2019-07-16
IL273411B1 (en) 2025-11-01
CN115925943A (zh) 2023-04-07
IL273411A (en) 2020-05-31
NZ762662A (en) 2024-03-22
KR20200061408A (ko) 2020-06-02
BR112020007725A2 (pt) 2020-10-06
EP3733704A1 (fr) 2020-11-04

Similar Documents

Publication Publication Date Title
IL273411A (en) Antibody against PD-L1 and its uses
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
ZA202000113B (en) Anti-ctla-4 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
ZA201902533B (en) Anti-pd-l1 antibodies and variants
IL271477A (en) Anti-cd166 antibodies and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
ZA201902265B (en) Anti-pd-1 antibodies and their uses
IL268206A (en) Antibodies directed against bcma and their use
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL279455A (en) ANTI-PD-1 antibodies and their uses
IL268051A (en) Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
EP3325513A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
IL269134A (en) Antibodies against PAR2 and their use
PL3426686T3 (pl) Humanizowane przeciwciała anty-pacap i ich zastosowanie
IL273157A (en) Antibodies specific to AXL and their uses
PL3464361T3 (pl) Przeciwciała anty-cd40 i ich zastosowania
IL272476A (en) Anti-Apelin antibodies and their uses
IL276675A (en) Anti-PD-1 antibodies and uses thereof
IL283180A (en) Anti-PD-1 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
IL274202A (en) Antibodies against Glyco-Moc1 and uses thereof
EP3733706A4 (fr) Anticorps anti-pd-l1 et son utilisation
SG11202003585VA (en) Anti-vista antibody and use thereof